Disclosure JR none related to current manuscript, outside of current manuscript: advisory board: Merck Sharp & Dohme (MSD), Boehringer Ingelheim, Bristol Myers Squibb (BMS), AstraZeneca, Roche, Bayer. Speaker: Pfizer; travel reimbursement: Ose Immunotherapeutics, BMS, AstraZeneca, Roche. LH none related to current manuscript, outside of current manuscript: research funding Roche Genentech, Boehringer Ingelheim, AstraZeneca (all institution, Takeda and Beigene under negotiation); advisory board: BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Boehringer Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: MSD, Lilly (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Benecke, Medtalks, VJOncology (self), interview sessions funded by Roche Genentech, Bayer, Lilly (institution); local PI of clinical trials: AstraZeneca, Novartis, BMS, MSD/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, Mirati. PB none related to current manuscript, outside of current manuscript: honoraria: AstraZeneca, Roche, BMS, Beigene, Takeda. Institutional grant: Roche, Pfizer. Travel grants: Amgen, Daiichi Sankyo.